Nvidia BioNeMo generative AI platform will
be used to accelerate the training of models on proprietary
data
NEW
YORK, June 10, 2024 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a patient focused
biopharmaceutical company, today announced the entry into a joint
development agreement with Wise Systems International SRL to
leverage artificial intelligence utilizing the BioNeMo AI platform
of Nvidia.
BioNeMo provides researchers and developers a fast and easy
way to build and integrate state-of-the-art generative AI
applications across the entire drug discovery pipeline—from target
identification to lead optimization—with AI workflows. With the
help of SRL, Hoth Therapeutics will have the ability to identify,
create and leverage its pipeline for additional therapeutics and to
further increase value of its assets.
Robert Antofe of Wise Systems International SRL commented,
"We're excited to work with Hoth and leverage our existing AI
expertise to help bring further value to both companies through the
development of Hoth Therapeutics AI initiatives."
"We believe the Nvidia BioNeMo platform is best in class and
with SRL's assistance we can better grow our IP, leverage our
existing pipeline and deliver exciting novel therapeutics to
patients in need," said Robb Knie,
Chief Executive Office of Hoth Therapeutics.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a
clinical-stage biopharmaceutical company dedicated to developing
innovative, impactful, and ground-breaking treatments with a goal
to improve patient quality of life. We are a catalyst in
early-stage pharmaceutical research and development, elevating
drugs from the bench to pre-clinical and clinical testing.
Utilizing a patient-centric approach, we collaborate and partner
with a team of scientists, clinicians, and key opinion leaders to
seek out and investigate therapeutics that hold immense potential
to create breakthroughs and diversify treatment options. To learn
more, please visit https://ir.hoththerapeutics.com/ .
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-joint-development-agreement-with-wise-systems-international-srl-to-utilize-artificial-intelligence-for-drug-discovery-302168103.html
SOURCE Hoth Therapeutics, Inc.